From HTS to phase i: The institute for therapeutics discovery and development at the university of minnesota

Peter I. Dosa; Gunda I. Georg; Vadim J. Gurvich; Jon E. Hawkinson; Michael A. Walters; Henry L. Wong

doi:10.2174/1386207317666140109122033

From HTS to phase i: The institute for therapeutics discovery and development at the university of minnesota

Peter I. Dosa, Gunda I. Georg, Vadim J. Gurvich, Jon E. Hawkinson, Michael A. Walters, Henry L. Wong

Medicinal Chemistry

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

The high-throughput screening core at the University of Minnesota is part of the Institute for Therapeutics Discovery and Development (ITDD), a comprehensive drug discovery and development center. The Institute provides scientific services to both academic and business communities and supports translational medicine via collaborations and contractual work. The ITDD is well-known for its broad range of screening capabilities and offers extensive medicinal chemistry expertise along with GMP scale-up and pre-clinical pharmacology support.

Original language	English (US)
Pages (from-to)	231-240
Number of pages	10
Journal	Combinatorial Chemistry and High Throughput Screening
Volume	17
Issue number	3
DOIs	https://doi.org/10.2174/1386207317666140109122033
State	Published - Mar 2014

Keywords

Drug development
Drug discovery
Good manufacturing practices (GMP)
High throughput screening (HTS)
Medicinal chemistry
Pharmacology
Scale-up
Translational science

Access

10.2174/1386207317666140109122033

OpenUrl availability

Full text

Cite this

@article{24bea7bd89794df39f444c89a2d70c30,

title = "From HTS to phase i: The institute for therapeutics discovery and development at the university of minnesota",

abstract = "The high-throughput screening core at the University of Minnesota is part of the Institute for Therapeutics Discovery and Development (ITDD), a comprehensive drug discovery and development center. The Institute provides scientific services to both academic and business communities and supports translational medicine via collaborations and contractual work. The ITDD is well-known for its broad range of screening capabilities and offers extensive medicinal chemistry expertise along with GMP scale-up and pre-clinical pharmacology support.",

keywords = "Drug development, Drug discovery, Good manufacturing practices (GMP), High throughput screening (HTS), Medicinal chemistry, Pharmacology, Scale-up, Translational science",

author = "Dosa, {Peter I.} and Georg, {Gunda I.} and Gurvich, {Vadim J.} and Hawkinson, {Jon E.} and Walters, {Michael A.} and Wong, {Henry L.}",

year = "2014",

month = mar,

doi = "10.2174/1386207317666140109122033",

language = "English (US)",

volume = "17",

pages = "231--240",

journal = "Combinatorial Chemistry and High Throughput Screening",

issn = "1386-2073",

publisher = "Bentham Science Publishers B.V.",

number = "3",

}

TY - JOUR

T1 - From HTS to phase i

T2 - The institute for therapeutics discovery and development at the university of minnesota

AU - Dosa, Peter I.

AU - Georg, Gunda I.

AU - Gurvich, Vadim J.

AU - Hawkinson, Jon E.

AU - Walters, Michael A.

AU - Wong, Henry L.

PY - 2014/3

Y1 - 2014/3

N2 - The high-throughput screening core at the University of Minnesota is part of the Institute for Therapeutics Discovery and Development (ITDD), a comprehensive drug discovery and development center. The Institute provides scientific services to both academic and business communities and supports translational medicine via collaborations and contractual work. The ITDD is well-known for its broad range of screening capabilities and offers extensive medicinal chemistry expertise along with GMP scale-up and pre-clinical pharmacology support.

AB - The high-throughput screening core at the University of Minnesota is part of the Institute for Therapeutics Discovery and Development (ITDD), a comprehensive drug discovery and development center. The Institute provides scientific services to both academic and business communities and supports translational medicine via collaborations and contractual work. The ITDD is well-known for its broad range of screening capabilities and offers extensive medicinal chemistry expertise along with GMP scale-up and pre-clinical pharmacology support.

KW - Drug development

KW - Drug discovery

KW - Good manufacturing practices (GMP)

KW - High throughput screening (HTS)

KW - Medicinal chemistry

KW - Pharmacology

KW - Scale-up

KW - Translational science

UR - http://www.scopus.com/inward/record.url?scp=84897997970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897997970&partnerID=8YFLogxK

U2 - 10.2174/1386207317666140109122033

DO - 10.2174/1386207317666140109122033

M3 - Article

C2 - 24409956

AN - SCOPUS:84897997970

SN - 1386-2073

VL - 17

SP - 231

EP - 240

JO - Combinatorial Chemistry and High Throughput Screening

JF - Combinatorial Chemistry and High Throughput Screening

IS - 3

ER -

From HTS to phase i: The institute for therapeutics discovery and development at the university of minnesota

Abstract

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this